Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials
Metrics: PDF 999 views | HTML 1253 views | ?
Hongliang Zhang1, Zhenguang Huang1, Xiaoqin Zou1, Taotao Liu1
1Pharmacy Department, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China
Taotao Liu, email: firstname.lastname@example.org
Keywords: bevacizumab, wound-healing complications, systematic review, meta-analysis
Received: June 29, 2016 Accepted: October 03, 2016 Published: October 14, 2016
A meta-analysis was conducted to estimate the risk of wound-healing complications in patients who treated with neoadjuvant-adjuvant bevacizumab in various oncological indications. We searched PUBMED, EMBASE and the Cochrane Library through June 2016 to identify randomized controlled trials of bevacizumab and wound-healing complications. Seven RCTs studies involving 5,147 participants were included in the analysis. Compared with routine therapy, bevacizumab increased the incidence of wound-healing complications for various cancers. The pooled estimate of odds ratio (OR) was 2.32, and the 95 % confidence intervals (CI) was 1.43 to 3.75. (P < 0.001). Subgroup analyses revealed the similar result in colon carcinoma patients. In conclusion, bevacizumab increases the incidence of wound-healing complications for cancers especially for colon neoplasms patients. However, the adverse effect is not appeared in breast cancer, metastatic renal cell carcinoma, non-small-cell lung cancer and gastro-oesophageal adenocarcinoma. Due to the findings relying chiefly on data from single or two studies, hence, further research is required to assess the wound-healing complications risk of bevacizumab in each oncological indication.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.